Dr. Reddy's Laboratories

Global Nasal delivery devices Markets, 2019-2020 & 2027: Rising Adoption of Self-Administration Practices & Consolidation of Nasal Delivery Device Industry

Retrieved on: 
Monday, December 7, 2020
Health sciences, Health care, Health, Dosage forms, Asthma, Respiratory therapy, Inhaler, Puffer, Dr. Reddy's Laboratories, Novartis, Pharmaceutical industry in India, Medication

The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027.

Key Points: 
  • The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027.
  • An inhaler (also known as a pump, puffer, or allergy spray) is a nasal delivery device used for delivering medicines into the lungs via person's breathing mechanism.
  • This device helps deliver medical treatment to the targeted region of the body, thereby reducing the side effects of oral medications.
  • ; Cadila Pharmaceuticals Ltd.; Novartis AG; Dr. Reddy's Laboratories; and Neurelis, Inc. are among the leading companies operating in the nasal delivery devices market.

Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India

Retrieved on: 
Tuesday, December 1, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Health care, COVID-19 pandemic in Russia, Gam-COVID-Vac, Science and technology in Russia, Vaccines, Dr. Reddy's Laboratories, Vaccine

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India.
  • The clinical trials are being conducted by JSS Medical Research as the clinical research partner.
  • Recently, RDIF announced the second interim analysis of clinical trial data, which showed 91.4% efficacy for the vaccine on day 28 after the first dose; vaccine efficacy over 95% 42 days after the first dose.
  • In September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.

Dr. Reddy’s to Acquire Select Anti-Allergy Brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan  

Retrieved on: 
Saturday, November 28, 2020
Biotechnology, Pharmaceutical, Health, Medical specialties, Immunology, Organic compounds, Allergology, Glucocorticoids, Pregnanes, Mineralocorticoids, Mometasone, Progestogens, Dr. Reddy's Laboratories, Azelastine, Rhinitis

The acquired brands represent two types of products, (a) mometasone mono product and (b) combination of mometasone with azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

Key Points: 
  • The acquired brands represent two types of products, (a) mometasone mono product and (b) combination of mometasone with azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.
  • M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) of Dr. Reddys said, The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important core markets for us.
  • Momat Rino, the largest brand acquired, has recently received OTC registration in Russia and this will enable accelerated access of this product to patients.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Global $95.67 Bn Nasal Delivery Devices Market Forecast to 2027 with COVID-19 Impact Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, November 27, 2020
Companies, Health sciences, Pharmaceutical companies, CAC 40, Sanofi, Dr. Reddy's Laboratories, Pfizer, Pharmaceutical industry, Novartis, Merck & Co., AstraZeneca

The "Nasal delivery devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Type; Delivery Technologies; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nasal delivery devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Type; Delivery Technologies; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to reach US$ 95,676.62 million by 2027 from US$ 58,502.18 million in 2019.
  • The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027.
  • ; AstraZeneca; Pfizer Inc.; BD; Sanofi; Merck & Co. Inc.; Cadila Pharmaceuticals Ltd.; Novartis AG; Dr. Reddy's Laboratories; and Neurelis, Inc. are among the leading companies operating in the nasal delivery devices market.

Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor

Retrieved on: 
Monday, November 9, 2020
Pharmaceutical, Health, Oncology, Clinical trials, NIFTY 50, Dr. Reddy's Laboratories, Companies, Dermatology, Economy of India, Business

Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

Key Points: 
  • Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.
  • We look forward to conducting clinical trials to further explore this combination.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

Retrieved on: 
Thursday, October 29, 2020
General Health, Health, Science, Pharmaceutical, Research, Biotechnology in India, Vaccines, Medical specialties, Health care, Medicine, Dr. Reddy's Laboratories, NIFTY 50, Biotechnology Industry Research Assistance Council, Department of Biotechnology, Vaccine, Gam-COVID-Vac, Good clinical laboratory practice, Dr. Reddy’s, RDIF:, DBT, BIRAC:

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.
  • Further, the Company will have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine.
  • Satish Reddy, Chairman, Dr. Reddys Laboratories said, We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India.
  • We look forward to working with them to accelerate our efforts in bringing the vaccine to India.

Dr. Reddy's Laboratories Announces Appointment of New Chief Financial Officer

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, NIFTY 50, States and union territories of India, India, Chief financial officer, Dr. Reddy's Laboratories, New York Stock Exchange, Reddy

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designate) on November 2, 2020.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designate) on November 2, 2020.
  • The Board of Directors at their meeting held today, has approved his appointment as a Chief Financial Officer (KMP*) of the Company effective December 1, 2020.
  • In a career spanning over 33 years, Parag has held several leadership positions, contributing significantly to the financial performance of his organizations.
  • He has expertise in driving performance management of investments, financial result delivery and driving operating margin improvement through revenue & cost optimization across the value chain.

Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

Retrieved on: 
Saturday, October 17, 2020
Pharmaceutical, Health, Clinical trials, Health, Vaccines, Medicine, Gam-COVID-Vac, Dr. Reddy's Laboratories, Russian Direct Investment Fund, Clinical trial, Vaccine, COVID-19 vaccine

Earlier in September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.

Key Points: 
  • Earlier in September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.
  • As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddys upon regulatory approval in India.
  • This data will further strengthen the clinical development of Sputnik V vaccine in India.
  • Sputnik V is currently undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000.

Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

Retrieved on: 
Monday, October 12, 2020
Biotechnology, Pharmaceutical, Health, NIFTY 50, Life sciences, Companies, Industries, Dr. Reddy's Laboratories, Biotechnology, Biosimilar, Sun Pharma, Lupin Limited

The operator will provide instructions on asking questions before and during the call.

Key Points: 
  • The operator will provide instructions on asking questions before and during the call.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy’s Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission Targets

Retrieved on: 
Monday, October 5, 2020
General Health, Pharmaceutical, Health, Environment, Dr. Reddy's Laboratories, NIFTY 50, Environmentalism, Sustainability, Radar Doppler Multitarget, Companies, Economy of India, Articles

G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories, said, Continuous improvement in our environmental performance is a notable aspect of our sustainability journey.

Key Points: 
  • G V Prasad, Co-chairman and Managing Director, Dr. Reddys Laboratories, said, Continuous improvement in our environmental performance is a notable aspect of our sustainability journey.
  • We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet.
  • In the Pharmaceutical & Biotech sector globally, 17 companies have successfully set their emission reduction targets affirming their pledge to mitigate climate change impacts.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.